Skip to content

Application of Artificial Intelligence (AI) in the Interpretation of PD-L1 Expression in Lung Cancer

Application of Artificial Intelligence (AI) in the Interpretation of PD-L1 Expression in Lung Cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022640
Enrollment
Unknown
Registered
2019-04-19
Start date
2019-10-01
Completion date
Unknown
Last updated
2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Gold Standard:The mean value of the interpretations of PD-L1 (22C3) from 3 pathologists with more than 5 years of experience in clinical pathological diagnosis, based on the digital slides.
Index test:The&#32
Pannoramic&#32
(3DHISTECH)&#32
be&#32
used&#32
to&#32
PD-L1&#32
(22C3)&#32
IHC&#32
slides.&#32
Then,&#32
tumor&#32

Sponsors

Daping Hospital, Army Medical University, PLA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: We enrolled PD-L1 (antibody clonal:22C3) staining slides by immunohistochemical (IHC) of lung adenocarcinoma resected specimens from the department of pathology, Daping hospital after October 01, 2018. The tumor proportion score (TPS) of positive expression of PD-L1 was determined according to the following criteria: TPS refers to the percentage of tumor cells stained with partial or complete membrane (1+) in all tumor cells (negative and positive) present in the sample. Only visible and clear membrane staining of tumor cells, partial or complete cell membrane staining score (1+) will be scored; stained immune cells and cytoplasmic staining cells were not involved in the scoring.

Exclusion criteria

Exclusion criteria: Core needle and bronchial biopsy samples, malignant pleural effusion cell blocks. Lung squamous cell carcinoma, large cell carcinoma, small cell carcinoma and other non-adenocarcinoma samples. Patients who had either received chemotherapy, radiotherapy or targeted therapy before surgery.

Design outcomes

Primary

MeasureTime frame
PD-L1 positive tumor ratio score;

Countries

China

Contacts

Public ContactHua-liang Xiao

Daping Hospital, Army Medical University, PLA

dpbl_xhl@126.com+86 13678475660

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026